Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 8/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015351 | 0.90 | RAF1 (0.50) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL769541 | 0.89 | RAF1 (0.64) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4903102 | 0.89 | RAF1 (0.48) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1015645 | 0.87 | CNR2 (0.47) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL11966207 | 0.87 | RAF1 (0.47) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1011493 | 0.86 | RAF1 (0.49) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL770045 | 0.85 | RAF1 (0.50) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL11293751 | 0.85 | RAF1 (0.50) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL769245 | 0.85 | RAF1 (0.50) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL17732309 | 0.84 | RAF1 (0.49) | RAF1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-10499640-B2 | Herbicidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2019-12-10 | — | — | US | disclosed |
| US-10499640-B2 | Herbicidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2019-12-10 | — | — | US | disclosed |
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170318810-A1 | Herbicidal Compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2017-11-09 | — | — | US | disclosed |
| US-20170318810-A1 | Herbicidal Compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2017-11-09 | — | — | US | disclosed |
| US-20170318810-A1 | Herbicidal Compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2017-11-09 | — | — | US | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-9320739-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| EP-2947072-A1 | 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES | Ambit Biosciences Corporation (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150246042-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2268623-B1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8969587-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-8618289-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2011-05-19 | — | — | US | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | RAF1 2/4885MAPK14 145/4885MAPK13 117/4885 |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | RAF1 2/4885MAPK14 80/4885MAPK13 76/4885 |
| US-10499640-B2 | Herbicidal compounds | DDT, HPD, CBR3 | RAF1 1376/4885MAPK14 3473/4885MAPK13 4220/4885 |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | RAF1 2/4885MAPK14 145/4885MAPK13 117/4885 |
| US-20170318810-A1 | Herbicidal Compounds | DDT, HPD, CBR3 | RAF1 1376/4885MAPK14 3473/4885MAPK13 4220/4885 |
| US-20150246042-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | RAF1 2/4885MAPK14 145/4885MAPK13 117/4885 |
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | RAF1 944/4885MAPK14 694/4885MAPK13 670/4885 |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | RAF1 2/4885MAPK14 145/4885MAPK13 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.